Longitudinal Effect of Antiretroviral Therapy on Markers of Hepatic Toxicity: Impact of Hepatitis C Coinfection
Open Access
- 1 August 2004
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 39 (3) , 402-410
- https://doi.org/10.1086/422142
Abstract
To characterize longitudinal hepatic toxicity of antiretroviral therapy in HIV-infected women with and without hepatitis C virus (HCV) infection, we measured alanine and aspartate aminotransferase values among women initiating highly active antiretroviral therapy (HAART). For 312 HIV/HCV coinfected women who received HAART for a mean of 1.8 years, the prevalence of elevated aminotransferase levels >3 times and >5 times the upper limit of normal (ULN) was low (P values for trend of .007–.06), but mean values among 128 women receiving therapy with nonnucleoside reverse-transcriptase inhibitors remained stable (from decreases of 1.65% to increases of 7.57% of the ULN per year; P values of .19–.71). Our findings lend support to assertions that antiretroviral therapy is safe for women with HCV infection.Keywords
This publication has 22 references indexed in Scilit:
- Incidence of Liver Injury After Beginning Antiretroviral Therapy with Efavirenz or NevirapineHIV Research & Clinical Practice, 2003
- Liver injury after beginning antiretroviral therapy in HIV/hepatitis C virus co-infected patients is not related to immune reconstitutionAIDS, 2002
- Incidence of and Risk Factors for Severe Hepatotoxicity Associated with Antiretroviral Combination TherapyThe Journal of Infectious Diseases, 2002
- Severity and correlates of liver disease in hepatitis C virus-infected injection drug usersHepatology, 2002
- Hepatotoxicity Development During Antiretroviral Therapy Containing Protease Inhibitors in Patients With HIVJAIDS Journal of Acquired Immune Deficiency Syndromes, 2002
- Low Frequency of Severe Hepatotoxicity and Association With HCV Coinfection in HIV-Positive Patients Treated With HAARTJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Risk Factors for Severe Hepatic Injury After Introduction of Highly Active Antiretroviral TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infectionAIDS, 2000
- Hepatitis B or Hepatitis C Virus Infection Is a Risk Factor for Severe Hepatic Cytolysis after Initiation of a Protease Inhibitor-Containing Antiretroviral Regimen in Human Immunodeficiency Virus-Infected PatientsAntimicrobial Agents and Chemotherapy, 2000
- Hepatotoxicity Associated With Antiretroviral Therapy in Adults Infected With Human Immunodeficiency Virus and the Role of Hepatitis C or B Virus InfectionJAMA, 2000